MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis

Tuschl, 2001, Identification of novel genes coding for small expressed RNAs, Science, 294, 853, 10.1126/science.1064921

Croce, 2011, Non-coding RNAs in cancer initiation and progression and as novel biomarkers, Mol Oncol, 5, 483, 10.1016/j.molonc.2011.10.003

Croce, 2006, MicroRNA signatures in human cancers, Nat Rev Cancer, 6, 857, 10.1038/nrc1997

Luo, 2015, MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1, FEBS J, 282, 579, 10.1111/febs.13167

Wang, 2015, miR-486 regulates metastasis and chemosensitivity in hepatocellular carcinoma by targeting CLDN10 and CITRON, Hepatol Res, 45, 1312, 10.1111/hepr.12500

Donahue, 2014, Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer, Oncogene, 33, 1181, 10.1038/onc.2013.42

Litman, 2014, Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status, Cell Oncol (Dordr), 37, 215, 10.1007/s13402-014-0176-6

Lin, 2016, Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma, Exp Ther Med, 12, 3411, 10.3892/etm.2016.3783

Haier, 2009, Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas, Ann Surg Oncol, 16, 2339, 10.1245/s10434-009-0531-4

Philip, 2012, MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer, Br J Cancer, 107, 1354, 10.1038/bjc.2012.383

Myklebost, 2012, Modulation of the osteosarcoma expression phenotype by microRNAs, PLoS One, 7, e48086, 10.1371/journal.pone.0048086

Bhatia, 2015, MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors, Blood, 125, 1302, 10.1182/blood-2014-06-581926

Li, 2013, miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops, Cell Res, 23, 274, 10.1038/cr.2012.174

Yousef, 2016, Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell-Cell Communication in Renal Cell Carcinoma, Eur Urol Focus, 2, 210, 10.1016/j.euf.2015.11.006

Zhao, 2016, Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study, Oncotarget, 7, 41575, 10.18632/oncotarget.9491

Jiang, 2015, The expression and Clinical significance of plasma miR-486 and miR-499 in lung cancer

Yang, 2011, Circulating miRNA signature for early diagnosis of lung cancer, EMBO Mol Med, 3, 436, 10.1002/emmm.201100155

Mutti, 2013, Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer, Biomarkers, 18, 679, 10.3109/1354750X.2013.845610

Jiang, 2011, Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers, BMC Cancer, 11, 374, 10.1186/1471-2407-11-374

Katz, 2011, Plasma microRNAs as potential biomarkers for non-small-cell lung cancer, Lab Invest, 91, 579, 10.1038/labinvest.2010.194

Siwicki, 2017, Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection, Cell Oncol (Dordr), 40, 529, 10.1007/s13402-017-0334-8

Takahashi, 2016, Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma, Sci Rep, 6, 31389, 10.1038/srep31389

Ju, 2016, Expression of miR-486 in serum of patients with gastric cancer and its significance, Acta Academiae Medicinae Nanjing, 36, 524

Feng, 2016, Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study, J Thorac Dis, 8, 1645, 10.21037/jtd.2016.06.21

Zhao, 2016, Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study, Ann Surg, 263, 1173, 10.1097/SLA.0000000000001345

Zang, 2016, The expression and clinical significance of plasma miR-486 and miR-499 in patients with lung cancer, Tianjin Yi Yao, 44, 1367

Jiang, 2010, Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers, Int J Cancer, 127, 2870, 10.1002/ijc.25289

Jin, 2014, A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer, Br J Cancer, 110, 2291, 10.1038/bjc.2014.119

Wu, 2016, A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles, Mol Med Rep, 13, 4643, 10.3892/mmr.2016.5114

Shen, 2010, Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer, J Clin Oncol, 28, 1721, 10.1200/JCO.2009.24.9342

Yuan, 2015, MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer, PLoS One, 10, e0134220, 10.1371/journal.pone.0134220

Tommasi, 2016, miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome, Tumour Biol, 37, 5503, 10.1007/s13277-015-4391-1

Han, 2016, miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value, Oncotarget, 7, 15840, 10.18632/oncotarget.7417

Tian, 2016, miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1, Biomed Pharmacother, 80, 220, 10.1016/j.biopha.2016.03.020

Yu, 2016, Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer, Oncotarget, 7, 10594, 10.18632/oncotarget.7236

Bossuyt, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009

Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z

Altman, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Irwig, 2005, The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed, J Clin Epidemiol, 58, 882, 10.1016/j.jclinepi.2005.01.016